Doravirine 100 mg
| Product Overview | |
| Generic Name | Doravirine 100 mg |
| Brand Name(s) | Pifeltro® |
| Form | 30 Film‑coated oral tablets |
| Strength | 100mg Tablets |
| Therapeutic Class | Non‑nucleoside reverse transcriptase inhibitor (NNRTI) |
| ATC Code | J05AG06 |
| Manufacturing & Regulatory | |
| Manufacturer | Merck & Co (developer & manufacturer of Pifeltro) |
| Country | India/USA/EU |
| GMP Compliance | WHO-GMP |
| DMF/CEP | Type II |
| COFEPRIS | Pending |
| Free Sale Certificate | Yes |
| Logistics & Export | |
| MOQ | 10 pks |
| Shelf Life | 24 Months |
| Storage | Store below 25 °C; protect from moisture/light |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | Provided per batch |
| SDS | Available from manufacturer |
| CTD Summary | Upon Request |
Description
Indications & Usage: Doravirine is an NNRTI indicated for the treatment of HIV‑1 infection in treatment-naïve adults and in regimen-switch patients with virologic suppression (<50 copies/mL). It’s administered once daily (100 mg) with or without food and typically used in combination with other ARVs. Doravirine avoids common NNRTI resistance mutations and has fewer drug–drug interactions.
